New Zealand's controversial medicines purchasing agency Pharmac has announced that it will fund MSD's KEYTRUDA (pembrolizumab) and Roche's TECENTRIQ (atezolizumab) for people with locally advanced and metastatic non-small cell lung cancer.
The long wait is finally over for New Zealand's lung cancer patients
March 13, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
Trump's language on pricing matches Australia's reflex response to PBS criticism
May 13, 2025 - - Latest News -
Health stakeholders welcome the reappointment of Mark Butler
May 12, 2025 - - Latest News -
Pharma stocks rise in response to Trump's 'MFN' executive order
May 12, 2025 - - Latest News -
Lilly touts weight management results in new head-to-head study
May 12, 2025 - - Latest News -
Experienced industry executive appointed chair of Tryptamine Therapeutics
May 12, 2025 - - Australian Biotech -
Monash scientists secure MRFF funding to find new medicines for dementia by 'lighting up' human brain cells
May 12, 2025 - -
Radiopharm Theranostics accelerates 177Lu-RAD204 Phase 1 dose escalation trial
May 12, 2025 - - Australian Biotech